Session 8, Abstract 49
GENOMIC CHARACTERIZATION OF LIQUID BIOPSY IN TREATMENT-NAIVE METASTATIC PROSTATE CANCER USING THE HIGH-DEFINITION SINGLE CELL ANALYSIS PLATFORM
Paymaneh D. Malihi1, Isla Garraway2, Michael Morikado1*, James Hicks1, Sandy T. Liu2, Carmen Ruiz Velasco1, Anders Carlsson1 and Anand Kolatkar1 (Peter Kuhn1), 1Department of Biological Sciences, Bridge Institute, University of Southern California, Los Angeles, CA, USA, 2Department of Urology, University of California Los Angeles, Los Angeles, CA, USA
Prostate cancer is the second leading cause of cancer death for men in the U.S. with approximately 1 in 7 men diagnosed during their lifetime. Following radical prostatectomy, which is the “gold standard” therapy for prostate cancer, androgen deprivation therapy (ADT) is administered to ease tumor growth. However, despite early response to ADT, castration-resistant prostate cancer (CRPC) frequently develops within 3 years. In such cases, patients resort to platinum-based chemotherapy, which does not address patients’ needs for both a more aggressive and personalized treatment. Using the High-Definition Single Cell Analysis (HD-SCA) platform, circulating tumor cells (CTCs) from peripheral blood, disseminating tumor cells (DTCs) from bone marrow aspirates, and cells from the primary tumor and bone lesions of treatment-naïve metastatic castration sensitive prostate cancer (mCSPC) patients are analyzed for morphological, genomic, and proteomic profiling. We hypothesize that by comparison of CTCs, DTCs, and cells obtained from the primary tumor and bone lesions, we may be able to provide insight into the evolution of the disease to provide a more informed treatment plan for individuals. Using genomic data we may find specific aberrations associate with resistance to ADT or other treatments. Multiplexed proteomic analysis via imaging mass cytometry can supplement the genomic data. Preliminary data show clonality in DTCs and cells from the primary tumor and bone lesions as well as several hallmark genomic aberrations of prostate cancer including PTEN deletion. The HD-SCA platform for characterization of fluid biopsy as a noninvasive alternative to solid biopsy of the primary tumor tissue may result in the identification of predictive biomarkers, and such morphometric, genomic, and proteomic biomarkers could influence treatment decisions, resulting in a more personalized medicine to improve management of the disease before it progresses.